Stock Buybacks
By The Online Investor Staff, updated Wed., May. 27, 10:44 AM
| This Slide: #3 of 25 |
Slide #3. Regeneron Pharmaceuticals, Inc.
Company:
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
$Amount Authorized:
$5,000,000,000
Buyback Details:
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi (NASDAQ: SNY) intends to exit its investment in Regeneron shares. The shares being offered by Sanofi will be sold in an underwritten public offering. Sanofi currently owns approximately 23.2 million Regeneron shares and intends to sell approximately 12.8 million shares in the public offering.1 Sanofi also expects to grant the underwriters a 30-day option to purchase an additional 10% of the shares offered in the base offering. The registered offering and share repurchase will have no impact on the ongoing collaboration between Regeneron and Sanofi. Regeneron also announced today that subject to and immediately following the close of the secondary offering, Regeneron agreed to repurchase approximately $5 billion of common stock directly from Sanofi. The purchase price to be paid by Regeneron will be equal to the net offering price per share after deducting any underwriters' discount and commission. Regeneron will fund the purchase with a combination of $3.5 billion of cash on hand and $1.5 billion of fully-committed bridge financing from Goldman Sachs Bank USA.
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. Co.'s commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. Co.'s products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.
Regeneron Pharmaceuticals SEC Filing Email Alerts Service
Open the REGN Page at The Online Investor »
|
||||||||||||||||||||||||
Open the REGN Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Buy (2.95 out of 4) 34th percentile
(ranked lower than approx. 66% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
